Skip to main content
Arctic Bioscience logo

Arctic Bioscience — Investor Relations & Filings

Ticker · ABS ISIN · NO0010859580 LEI · 549300Z2HW6I989Q2C78 OL Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2022-10-31 Earnings Release
Country NO Norway
Listing OL ABS

About Arctic Bioscience

https://arctic-bioscience.com/

Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical and nutraceutical products derived from marine membrane lipids. The company utilizes proprietary technology to extract bioactive compounds from herring roe, sourced from sustainable, MSC-certified fisheries. Its nutraceutical product line, marketed under the brand name Romega, consists of high-DHA Omega-3 phospholipid extracts. The pharmaceutical division is focused on developing a novel drug candidate for the treatment of mild-to-moderate psoriasis, aligning with its mission to create therapies for autoimmune disorders. The company's work is supported by extensive research and development to validate the efficacy of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
Arctic Bioscience - Q3 2022 Operational update - Positive progress in both pharma and nutra
Earnings Release Classification · 98% confidence The document is explicitly titled "Press Release 31. October 2022" and provides key financial highlights (Revenues, EBITDA, Cash) for Q3 2022 compared to prior periods, along with operational updates and outlook. This structure—a brief announcement of period results, often including key figures in a table, but not the full comprehensive report—is characteristic of an Earnings Release (ER). It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR), as it focuses on highlights and is presented as a press release. It is also not a Call Transcript (CT) or an Investor Presentation (IP). Q3 2022
2022-10-31 English
Arctic Bioscience - Q3 2022 Operational update - Positive progress in both pharma and nutra
Interim / Quarterly Report Classification · 95% confidence The document is an 'Operational Update' for Q3 2022, which provides a comprehensive summary of financial performance (revenues, EBITDA, gross profit, cash position) and operational milestones for the specific quarter. It contains substantive financial data and analysis, distinguishing it from a mere announcement or a short press release. It fits the definition of an Interim/Quarterly Report (IR) as it covers a period shorter than a full fiscal year and provides detailed financial results. Q3 2022
2022-10-31 English
Arctic Bioscience - Clinical Trial Application for HRO350 Phase IIb submitted
Regulatory Filings Classification · 90% confidence The document is a short announcement titled "Arctic Bioscience - Clinical Trial Application for HRO350 Phase IIb submitted". It explicitly states that the Clinical Trial Application (CTA) has been submitted and discusses the next steps (patient enrollment). This is not a full financial report (like 10-K or IR), nor is it a transcript or a management discussion. It relates to the development of a drug candidate and the regulatory step of submitting a CTA. Among the provided codes, there is no specific code for a 'Clinical Trial Application Submission'. However, the content is a regulatory/operational update concerning drug development. Given the options, this type of announcement, which is a specific operational update that doesn't fit the financial or governance categories, is best categorized as a general Regulatory Filing (RNS) or potentially related to Intellectual Property (IP) if the CTA submission itself is considered an IP event, but RNS is the broader fallback for non-standard regulatory announcements. Since it is a direct announcement of a regulatory submission, RNS is the most appropriate general classification, as it is not a standard financial report or a specific management/director change.
2022-10-10 English
Arctic Bioscience - Clinical Trial Application for HRO350 Phase IIb - update
Regulatory Filings Classification · 100% confidence The document is a short update titled "Arctic Bioscience - Clinical Trial Application for HRO350 Phase IIb - update". It references previous announcements and provides a timeline for submitting a Clinical Trial Application (CTA) for a drug candidate (HRO350). This type of announcement, detailing progress on clinical trials, regulatory submissions, or specific product development milestones, does not fit neatly into the primary financial reporting categories (10-K, IR, ER). It is an announcement concerning the company's operations and pipeline, which often falls under general regulatory disclosures or investor relations updates. Given the specific nature of the update (clinical trial application progress) and the lack of a better fit among the provided options, it is best classified as a general Regulatory Filing (RNS), as it is a specific, non-standard operational update subject to disclosure requirements, or potentially a specialized Investor Relations update, but RNS serves as the best general regulatory announcement category here.
2022-10-03 English
Arctic Bioscience - Webcast from Capital Markets Update available on web
Report Publication Announcement Classification · 98% confidence The document explicitly states that a 'Webcast from Capital Markets Update' recording is now available and provides a link to access it. This is an announcement about the availability of content from a specific corporate event (Capital Markets Update), rather than the full transcript (CT) or a general investor presentation (IP). Since the content is a recording of an update event, and the document's primary function is to announce its availability, it aligns best with the 'Report Publication Announcement' (RPA) category, which covers announcements regarding the release or publication of company materials/events. The document is also very short (1608 chars), supporting the RPA classification over the full content classification.
2022-09-26 English
Arctic Bioscience - Capital markets update
Investor Presentation Classification · 99% confidence The document is explicitly titled "Company Presentation" and has the subtitle "Capital Markets Update, Oslo 21 September 2022". It contains an agenda, detailed slides on technology, R&D, pharmaceutical pipeline (HRO350 for psoriasis and a drug candidate for premature infants), financial highlights (H1-2022), business outlook, and a milestone overview. This structure is characteristic of a presentation given to investors or analysts to update them on the company's strategy, progress, and financial standing, which aligns perfectly with the definition of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a formal report (AR/IR).
2022-09-21 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.